Decibel Therapeutics Key Executives
This section highlights Decibel Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Decibel Therapeutics
(Showing 0 of )
Decibel Therapeutics Earnings
This section highlights Decibel Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
$4.91
Stock Price
$123.37M
Market Cap
68
Employees
Boston, MA
Location
Financial Statements
Access annual & quarterly financial statements for Decibel Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $40.33M | $29.85M | $25.32M | $29.41M | $26.17M |
| General and Administrative Expenses | $23.63M | $20.38M | $14.24M | $14.68M | $11.69M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $23.63M | $20.38M | $14.24M | $14.68M | $11.69M |
| Other Expenses | $- | $12.00K | $171.00K | $- | $- |
| Operating Expenses | $63.96M | $50.23M | $39.56M | $44.08M | $37.86M |
| Cost and Expenses | $63.96M | $50.23M | $39.56M | $44.08M | $37.86M |
| Interest Income | $1.19M | $193.00K | $55.00K | $1.41M | $1.70M |
| Interest Expense | $1.19M | $- | $- | $- | $- |
| Depreciation and Amortization | $1.46M | $1.41M | $1.64M | $1.77M | $1.47M |
| EBITDA | $-62.49M | $-48.82M | $-39.56M | $-42.31M | $-36.38M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-63.96M | $-50.23M | $-39.56M | $-44.08M | $-37.86M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $1.19M | $205.00K | $226.00K | $1.41M | $1.70M |
| Income Before Tax | $-62.77M | $-50.03M | $-39.34M | $-42.67M | $-36.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $240.00K | $1.80M | $-1.70M | $-1.41M | $1.70M |
| Net Income | $-63.01M | $-51.82M | $-37.64M | $-41.26M | $-36.16M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-2.52 | $-2.38 | $-1.63 | $-5.61 | $-4.98 |
| EPS Diluted | $-2.52 | $-2.38 | $-1.63 | $-5.61 | $-4.98 |
| Weighted Average Shares Outstanding | 24.96M | 21.73M | 23.12M | 7.36M | 7.26M |
| Weighted Average Shares Outstanding Diluted | 24.96M | 21.73M | 23.12M | 7.36M | 7.26M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $12.83M | $7.93M | $11.59M | $10.03M | $11.24M | $7.47M | $7.98M | $9.02M | $6.83M | $6.02M | $7.90M | $4.69M | $5.30M | $7.44M | $3.17M |
| General and Administrative Expenses | $6.21M | $6.19M | $4.89M | $6.32M | $5.86M | $6.55M | $4.92M | $5.68M | $4.90M | $4.88M | $5.11M | $2.40M | $2.56M | $4.18M | $3.26M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $6.21M | $6.19M | $4.89M | $6.32M | $5.86M | $6.55M | $4.92M | $5.68M | $4.90M | $4.88M | $5.11M | $2.40M | $2.56M | $4.18M | $3.26M |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-25.00K | $25.00K | $- | $- |
| Operating Expenses | $19.04M | $14.12M | $16.49M | $16.35M | $17.10M | $14.02M | $12.90M | $14.70M | $11.73M | $10.90M | $13.01M | $7.09M | $7.85M | $11.61M | $6.44M |
| Cost and Expenses | $19.04M | $14.12M | $16.49M | $16.35M | $17.10M | $14.02M | $12.90M | $14.70M | $11.73M | $10.90M | $13.01M | $7.09M | $7.85M | $11.61M | $6.44M |
| Interest Income | $976.00K | $878.00K | $660.00K | $374.00K | $95.00K | $63.00K | $52.00K | $33.00K | $75.00K | $33.00K | $-48.00K | $2.00K | $22.00K | $79.00K | $217.00K |
| Interest Expense | $- | $- | $660.00K | $374.00K | $95.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $323.00K | $340.00K | $374.00K | $359.00K | $362.00K | $367.00K | $309.00K | $340.00K | $337.00K | $427.00K | $345.00K | $394.00K | $416.00K | $487.00K | $554.00K |
| EBITDA | $-18.72M | $-13.78M | $-16.11M | $-15.99M | $-16.74M | $-13.65M | $-12.59M | $-14.36M | $-11.39M | $-10.48M | $-13.01M | $-6.69M | $-7.44M | $-11.13M | $-5.88M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-19.04M | $-14.12M | $-16.49M | $-16.35M | $-17.10M | $-14.02M | $-12.90M | $-14.70M | $-11.73M | $-10.90M | $-13.01M | $-7.09M | $-7.85M | $-11.61M | $-6.44M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $976.00K | $878.00K | $660.00K | $374.00K | $95.00K | $63.00K | $64.00K | $33.00K | $75.00K | $33.00K | $123.00K | $-23.00K | $47.00K | $79.00K | $217.00K |
| Income Before Tax | $-18.07M | $-13.24M | $-15.83M | $-15.97M | $-17.01M | $-13.96M | $-12.84M | $-14.67M | $-11.65M | $-10.87M | $-12.88M | $-7.11M | $-7.81M | $-11.54M | $-6.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $80.00K | $61.00K | $112.00K | $30.00K | $38.00K | $60.00K | $65.00K | $1.73M | $- | $- | $-345.00K | $-2.00K | $-22.00K | $- | $- |
| Net Income | $-18.14M | $-13.30M | $-15.94M | $-16.00M | $-17.05M | $-14.02M | $-12.90M | $-16.40M | $-11.65M | $-10.87M | $-12.88M | $-7.11M | $-7.81M | $-11.54M | $-6.22M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.73 | $-0.53 | $-0.64 | $-0.64 | $-0.68 | $-0.56 | $-0.52 | $-0.66 | $-0.47 | $-0.90 | $-0.56 | $-0.97 | $-1.06 | $-1.57 | $-0.85 |
| EPS Diluted | $-0.73 | $-0.53 | $-0.64 | $-0.64 | $-0.68 | $-0.56 | $-0.52 | $-0.66 | $-0.47 | $-0.90 | $-0.56 | $-0.97 | $-1.06 | $-1.57 | $-0.85 |
| Weighted Average Shares Outstanding | 25.02M | 24.99M | 24.96M | 24.96M | 24.96M | 24.96M | 24.95M | 24.87M | 24.87M | 12.11M | 23.12M | 7.36M | 7.36M | 7.36M | 7.36M |
| Weighted Average Shares Outstanding Diluted | 25.02M | 24.99M | 24.96M | 24.96M | 24.96M | 24.96M | 24.95M | 24.87M | 24.87M | 12.11M | 23.12M | 7.36M | 7.36M | 7.36M | 7.36M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $34.61M | $36.45M | $27.74M | $18.60M | $11.32M |
| Short Term Investments | $69.95M | $112.29M | $26.57M | $13.71M | $70.94M |
| Cash and Short Term Investments | $104.56M | $148.75M | $54.31M | $32.31M | $82.26M |
| Net Receivables | $- | $11.40M | $1.24M | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $3.47M | $4.04M | $2.28M | $1.26M | $1.35M |
| Total Current Assets | $108.03M | $164.19M | $57.83M | $33.57M | $83.61M |
| Property Plant Equipment Net | $14.42M | $5.61M | $6.34M | $7.83M | $8.88M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $13.55M | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $924.00K | $1.13M | $3.12M | $1.44M | $800.00K |
| Total Non-Current Assets | $15.34M | $20.29M | $9.46M | $9.26M | $9.68M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $123.37M | $184.48M | $67.28M | $42.84M | $93.29M |
| Account Payables | $1.06M | $4.01M | $2.13M | $1.01M | $1.06M |
| Short Term Debt | $3.59M | $213.00K | $193.00K | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $16.86M | $- | $- |
| Other Current Liabilities | $17.79M | $16.31M | $193.00K | $8.44M | $9.94M |
| Total Current Liabilities | $22.44M | $20.54M | $19.37M | $9.45M | $11.00M |
| Long Term Debt | $10.47M | $4.21M | $4.90M | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $8.67M | $18.04M | $4.70M | $17.54M | $24.84M |
| Total Non-Current Liabilities | $19.14M | $22.25M | $9.60M | $17.54M | $24.84M |
| Other Liabilities | $- | $- | $201.00M | $- | $- |
| Total Liabilities | $41.58M | $42.79M | $229.97M | $26.99M | $35.84M |
| Preferred Stock | $- | $184.48M | $93.09M | $137.64M | $137.64M |
| Common Stock | $25.00K | $25.00K | $1.00K | $- | $- |
| Retained Earnings | $-277.52M | $-214.51M | $-162.69M | $-123.35M | $-80.68M |
| Accumulated Other Comprehensive Income Loss | $-223.00K | $-132.00K | $-1.00K | $10.00K | $-47.00K |
| Other Total Stockholders Equity | $359.51M | $171.83M | $-93.09M | $1.55M | $535.00K |
| Total Stockholders Equity | $81.79M | $141.69M | $-162.69M | $15.85M | $57.45M |
| Total Equity | $81.79M | $141.69M | $-162.69M | $15.85M | $57.45M |
| Total Liabilities and Stockholders Equity | $123.37M | $184.48M | $67.28M | $42.84M | $93.29M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $123.37M | $184.48M | $67.28M | $42.84M | $93.29M |
| Total Investments | $69.95M | $125.84M | $26.57M | $13.71M | $70.94M |
| Total Debt | $14.05M | $213.00K | $193.00K | $- | $- |
| Net Debt | $-20.55M | $-36.24M | $-27.55M | $-18.60M | $-11.32M |
Balance Sheet Charts
| Breakdown | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $39.80M | $38.06M | $34.61M | $36.68M | $56.45M | $10.78M | $36.45M | $51.41M | $37.69M | $52.24M | $27.74M | $5.20M | $18.60M |
| Short Term Investments | $38.50M | $49.88M | $69.95M | $75.26M | $69.20M | $123.66M | $112.29M | $92.48M | $118.08M | $129.84M | $26.57M | $- | $13.71M |
| Cash and Short Term Investments | $78.30M | $87.94M | $104.56M | $111.95M | $125.65M | $134.44M | $148.75M | $143.89M | $155.77M | $182.08M | $54.31M | $5.20M | $32.31M |
| Net Receivables | $- | $4.40M | $- | $10.00M | $10.00M | $10.00M | $11.40M | $3.14M | $1.72M | $4.24M | $1.24M | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $2.15M | $3.53M | $3.47M | $4.34M | $5.76M | $6.80M | $4.04M | $2.83M | $3.81M | $4.42M | $2.28M | $1.51M | $1.26M |
| Total Current Assets | $80.45M | $95.87M | $108.03M | $126.29M | $141.41M | $151.24M | $164.19M | $149.87M | $161.30M | $190.73M | $57.83M | $6.71M | $33.57M |
| Property Plant Equipment Net | $13.00M | $13.66M | $14.42M | $14.93M | $15.71M | $16.41M | $5.61M | $5.80M | $5.63M | $5.97M | $6.34M | $6.61M | $7.83M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $5.00M | $13.55M | $28.49M | $28.83M | $9.00M | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $934.00K | $924.00K | $924.00K | $1.06M | $1.16M | $1.13M | $1.13M | $1.13M | $1.13M | $1.38M | $3.12M | $1.54M | $1.44M |
| Total Non-Current Assets | $13.94M | $14.59M | $15.34M | $15.99M | $16.87M | $22.54M | $20.29M | $35.42M | $35.59M | $16.35M | $9.46M | $8.15M | $9.26M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $94.39M | $110.45M | $123.37M | $142.27M | $158.28M | $173.78M | $184.48M | $185.29M | $196.90M | $207.09M | $67.28M | $14.86M | $42.84M |
| Account Payables | $617.00K | $1.28M | $1.06M | $3.03M | $1.92M | $1.21M | $4.01M | $1.81M | $2.14M | $1.00M | $2.13M | $1.19M | $1.01M |
| Short Term Debt | $3.66M | $3.59M | $3.59M | $3.62M | $3.65M | $3.68M | $213.00K | $208.00K | $201.00K | $197.00K | $193.00K | $318.00K | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $13.80M | $16.86M | $10.21M | $- |
| Other Current Liabilities | $22.30M | $18.31M | $17.79M | $16.72M | $17.31M | $13.22M | $16.31M | $14.48M | $14.29M | $197.00K | $193.00K | $318.00K | $8.44M |
| Total Current Liabilities | $26.58M | $23.18M | $22.44M | $23.37M | $22.87M | $18.11M | $20.54M | $16.50M | $16.64M | $15.19M | $19.37M | $12.04M | $9.45M |
| Long Term Debt | $9.18M | $9.81M | $10.47M | $11.10M | $11.73M | $12.33M | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $5.31M | $7.62M | $8.67M | $10.98M | $11.82M | $15.23M | $22.25M | $14.63M | $10.85M | $11.63M | $9.60M | $12.81M | $17.54M |
| Total Non-Current Liabilities | $14.50M | $17.43M | $19.14M | $22.09M | $23.55M | $27.56M | $22.25M | $14.63M | $10.85M | $11.63M | $9.60M | $12.81M | $17.54M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $201.00M | $- | $- |
| Total Liabilities | $41.08M | $40.61M | $41.58M | $45.46M | $46.42M | $45.66M | $42.79M | $31.13M | $27.48M | $26.82M | $229.97M | $24.86M | $26.99M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $93.09M | $137.64M | $137.64M |
| Common Stock | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K | $25.00K | $1.00K | $- | $- |
| Retained Earnings | $-308.97M | $-290.82M | $-277.52M | $-261.58M | $-245.57M | $-228.53M | $-214.51M | $-201.61M | $-185.21M | $-173.56M | $-162.69M | $-149.81M | $-123.35M |
| Accumulated Other Comprehensive Income Loss | $-35.00K | $-61.00K | $-223.00K | $-503.00K | $-588.00K | $-527.00K | $-132.00K | $8.00K | $5.00K | $-21.00K | $-1.00K | $- | $10.00K |
| Other Total Stockholders Equity | $362.29M | $360.70M | $359.51M | $358.87M | $358.00M | $357.15M | $356.31M | $355.73M | $354.59M | $353.82M | $-93.09M | $2.17M | $1.55M |
| Total Stockholders Equity | $53.31M | $69.84M | $81.79M | $96.81M | $111.86M | $128.12M | $141.69M | $154.16M | $169.41M | $180.27M | $-162.69M | $-9.99M | $15.85M |
| Total Equity | $53.31M | $69.84M | $81.79M | $96.81M | $111.86M | $128.12M | $141.69M | $154.16M | $169.41M | $180.27M | $-162.69M | $-9.99M | $15.85M |
| Total Liabilities and Stockholders Equity | $94.39M | $110.45M | $123.37M | $142.27M | $158.28M | $173.78M | $184.48M | $185.29M | $196.90M | $207.09M | $67.28M | $14.86M | $42.84M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $94.39M | $110.45M | $123.37M | $142.27M | $158.28M | $173.78M | $184.48M | $185.29M | $196.90M | $207.09M | $67.28M | $14.86M | $42.84M |
| Total Investments | $38.50M | $49.88M | $69.95M | $75.26M | $69.20M | $128.66M | $125.84M | $120.97M | $146.91M | $138.84M | $26.57M | $- | $13.71M |
| Total Debt | $12.85M | $13.40M | $14.05M | $14.72M | $15.38M | $16.01M | $213.00K | $208.00K | $201.00K | $197.00K | $193.00K | $318.00K | $- |
| Net Debt | $-26.96M | $-24.67M | $-20.55M | $-21.96M | $-41.07M | $5.23M | $-36.24M | $-51.20M | $-37.49M | $-52.04M | $-27.55M | $-4.88M | $-18.60M |
Annual Cash Flow
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Net Income | $-63.01M | $-51.82M | $-39.34M | $-42.67M | $-36.16M |
| Depreciation and Amortization | $1.46M | $1.41M | $1.64M | $1.77M | $1.47M |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $3.20M | $2.82M | $2.81M | $952.00K | $455.00K |
| Change in Working Capital | $-618.00K | $3.49M | $2.25M | $-8.69M | $-957.00K |
| Accounts Receivables | $11.40M | $-10.16M | $-1.24M | $- | $- |
| Inventory | $- | $2.98M | $-1.08M | $- | $- |
| Accounts Payables | $-3.13M | $1.88M | $1.12M | $-56.00K | $605.00K |
| Other Working Capital | $-8.89M | $8.80M | $3.45M | $-8.63M | $-1.56M |
| Other Non Cash Items | $2.06M | $952.00K | $-33.00K | $-769.00K | $-890.00K |
| Net Cash Provided by Operating Activities | $-56.90M | $-43.15M | $-32.66M | $-49.41M | $-36.08M |
| Investments in Property Plant and Equipment | $-463.00K | $-745.00K | $-273.00K | $-717.00K | $-1.29M |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $-97.51M | $-197.46M | $-26.58M | $-31.67M | $-117.90M |
| Sales Maturities of Investments | $153.07M | $97.07M | $13.75M | $89.72M | $47.80M |
| Other Investing Activities | $- | $139.00K | $92.00K | $- | $- |
| Net Cash Used for Investing Activities | $55.10M | $-101.00M | $-13.01M | $57.34M | $-71.39M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $128.24M | $54.80M | $-5.00K | $56.00K |
| Common Stock Repurchased | $- | $-1.00K | $-15.00K | $-5.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-213.00K | $152.51M | $54.85M | $-5.00K | $55.06M |
| Net Cash Used Provided by Financing Activities | $-213.00K | $152.51M | $54.85M | $-5.00K | $55.06M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-2.01M | $8.37M | $9.18M | $7.92M | $-52.41M |
| Cash at End of Period | $35.57M | $37.58M | $29.22M | $20.04M | $12.12M |
| Cash at Beginning of Period | $37.58M | $29.22M | $20.04M | $12.12M | $64.53M |
| Operating Cash Flow | $-56.90M | $-43.15M | $-32.66M | $-49.41M | $-36.08M |
| Capital Expenditure | $-463.00K | $-745.00K | $-273.00K | $-717.00K | $-1.29M |
| Free Cash Flow | $-57.36M | $-43.90M | $-32.93M | $-50.13M | $-37.37M |
Cash Flow Charts
| Breakdown | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-18.14M | $-13.30M | $-15.94M | $-16.00M | $-17.05M | $-14.02M | $-12.90M | $-16.40M | $-11.65M | $-10.87M | $-12.88M | $-7.11M | $-7.81M | $-11.54M | $-6.22M |
| Depreciation and Amortization | $323.00K | $340.00K | $374.00K | $359.00K | $362.00K | $367.00K | $309.00K | $340.00K | $337.00K | $427.00K | $345.00K | $394.00K | $416.00K | $487.00K | $554.00K |
| Deferred Income Tax | $-355.00K | $- | $- | $- | $- | $297.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $1.37M | $977.00K | $637.00K | $876.00K | $845.00K | $842.00K | $371.00K | $1.04M | $764.00K | $646.00K | $2.23M | $185.00K | $179.00K | $225.00K | $260.00K |
| Change in Working Capital | $6.07M | $-5.21M | $6.93M | $615.00K | $1.75M | $-9.92M | $2.38M | $3.07M | $4.63M | $-6.60M | $5.17M | $-1.17M | $-710.00K | $-1.04M | $-5.16M |
| Accounts Receivables | $4.40M | $-4.40M | $10.00M | $1.40M | $- | $1.40M | $-8.26M | $-1.42M | $2.52M | $-3.00M | $- | $- | $- | $- | $- |
| Inventory | $3.35M | $- | $- | $- | $- | $-5.52M | $-1.02M | $4.26M | $3.16M | $-3.42M | $- | $- | $- | $- | $- |
| Accounts Payables | $-661.00K | $394.00K | $-2.15M | $1.12M | $704.00K | $-2.80M | $2.20M | $-327.00K | $1.14M | $-1.13M | $937.00K | $111.00K | $132.00K | $-57.00K | $-299.00K |
| Other Working Capital | $-1.02M | $-1.20M | $-920.00K | $-1.90M | $1.05M | $-3.00M | $8.45M | $4.82M | $973.00K | $-2.47M | $4.24M | $-1.28M | $-842.00K | $-982.00K | $-4.86M |
| Other Non Cash Items | $470.00K | $141.00K | $228.00K | $438.00K | $680.00K | $420.00K | $293.00K | $302.00K | $269.00K | $88.00K | $-7.00K | $20.00K | $-2.00K | $-44.00K | $-29.00K |
| Net Cash Provided by Operating Activities | $-10.27M | $-17.06M | $-7.77M | $-13.72M | $-13.41M | $-22.01M | $-9.54M | $-11.65M | $-5.65M | $-16.31M | $-5.15M | $-7.68M | $-7.92M | $-11.91M | $-10.60M |
| Investments in Property Plant and Equipment | $12.00K | $-266.00K | $-197.00K | $-45.00K | $-120.00K | $-101.00K | $-325.00K | $-318.00K | $-37.00K | $-65.00K | $-112.00K | $-10.00K | $-95.00K | $-56.00K | $-78.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-10.24M | $-2.92M | $-25.66M | $-32.61M | $- | $-39.25M | $-31.74M | $-18.50M | $-31.07M | $-116.16M | $-26.58M | $- | $- | $- | $-67.00K |
| Sales Maturities of Investments | $22.00M | $23.50M | $31.50M | $26.66M | $59.18M | $35.73M | $26.40M | $44.14M | $22.75M | $3.78M | $- | $- | $2.00M | $11.75M | $13.30M |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $97.00K | $- | $42.00K | $- | $- | $92.00K | $- | $- | $- |
| Net Cash Used for Investing Activities | $11.77M | $20.32M | $5.65M | $-6.00M | $59.06M | $-3.62M | $-5.56M | $25.32M | $-8.31M | $-112.44M | $-26.69M | $82.00K | $1.91M | $11.69M | $13.15M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $216.00K | $- | $- | $- | $- | $- | $- | $- | $128.24M | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-12.00K | $-3.00K | $- | $- | $-3.00K |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $206.00K | $197.00K | $-55.00K | $-54.00K | $-52.00K | $-52.00K | $151.00K | $51.00K | $-840.00K | $153.15M | $54.39M | $466.00K | $- | $- | $-3.00K |
| Net Cash Used Provided by Financing Activities | $206.00K | $197.00K | $-55.00K | $-54.00K | $-52.00K | $-52.00K | $151.00K | $51.00K | $-840.00K | $153.15M | $54.39M | $466.00K | $- | $- | $-3.00K |
| Effect of Forex Changes on Cash | $-337.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $1.71M | $3.46M | $-2.17M | $-19.77M | $45.60M | $-25.68M | $-14.96M | $13.72M | $-14.80M | $24.40M | $22.54M | $-7.13M | $-6.02M | $-212.00K | $2.56M |
| Cash at End of Period | $40.74M | $39.03M | $35.57M | $37.74M | $57.51M | $11.91M | $37.58M | $52.54M | $38.82M | $53.62M | $29.22M | $6.67M | $13.81M | $19.83M | $20.04M |
| Cash at Beginning of Period | $39.03M | $35.57M | $37.74M | $57.51M | $11.91M | $37.58M | $52.54M | $38.82M | $53.62M | $29.22M | $6.67M | $13.81M | $19.83M | $20.04M | $17.48M |
| Operating Cash Flow | $-10.27M | $-17.06M | $-7.77M | $-13.72M | $-13.41M | $-22.01M | $-9.54M | $-11.65M | $-5.65M | $-16.31M | $-5.15M | $-7.68M | $-7.92M | $-11.91M | $-10.60M |
| Capital Expenditure | $12.00K | $-266.00K | $-197.00K | $-45.00K | $-120.00K | $-101.00K | $-325.00K | $-318.00K | $-37.00K | $-65.00K | $-112.00K | $-10.00K | $-95.00K | $-56.00K | $-78.00K |
| Free Cash Flow | $-10.26M | $-17.32M | $-7.96M | $-13.76M | $-13.53M | $-22.11M | $-9.87M | $-11.97M | $-5.69M | $-16.37M | $-5.26M | $-7.69M | $-8.02M | $-11.96M | $-10.68M |
Decibel Therapeutics Dividends
Explore Decibel Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Decibel Therapeutics News
Read the latest news about Decibel Therapeutics, including recent articles, headlines, and updates.
Decibel Therapeutics' CVR Appears Around Fair Value
Decibel Therapeutics is being acquired by Regeneron for a cash consideration of $4/share and a CVR linked to DB-OTO. DB-OTO is a gene therapy for hearing loss, with a phase 1/2 trial underway. The CVR broadly pays out with the early stages of the Phase III trial and subsequently the filing of a BLA application (or European equivalent).
DECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel Therapeutics, Inc. - DBTX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Decibel Therapeutics, Inc. (NasdaqGS: DBTX) to Regeneron Pharmaceuticals, Inc. (NasdaqGS: REGN). Under the terms of the proposed transaction, shareholders of Decibel will receive only $4.00 in cash for each share of Decibel that they own, with an additional non-tradeable contingent value right (CVR) to receive.
Shareholder Alert: Ademi LLP investigates whether Decibel Therapeutics, Inc. has obtained a Fair Price in its transaction with Regeneron
MILWAUKEE , Aug. 9, 2023 /PRNewswire/ -- Ademi LLP is investigating Decibel (NASDAQ: DBTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Regeneron. Click here to learn how to join the action https://www.ademilaw.com/case/decibel-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.
DBTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Decibel Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Decibel Therapeutics, Inc. (NASDAQ: DBTX) to Regeneron Pharmaceuticals, Inc. is fair to Decibel shareholders. Under the merger, Decibel shareholders will receive $4.00 per share in cash and a non-tradeable contingent value right entitling such holders to receive up to $3.50 per share in cash if certain clinical development and regulatory milestones are achieved. Halper Sadeh encourages.
Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal
Decibel Therapeutics (NASDAQ: DBTX ) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (NASDAQ: REGN ). This deal has Regeneron Pharmaceuticals agreeing to acquire Decibel Therapeutics for $4 per share in cash.
Decibel Therapeutics shoots up 72% on Regeneron bid
Shares of Boston's Decibel Therapeutics Inc soared 72% in the first minutes of trading after Regeneron Pharmaceuticals weighed looks calculated to be a knock-out bid for the tiny drug developer. The deal values Decibel Therapeutics, which is working on treatments aimed at enhancing and restoring hearing and balance, at $109 million.
Regeneron buying small cap Decibel Therapeutics for $4 a share
Regeneron Pharmaceuticals Inc. REGN, +0.72% said Wednesday it would pay $4 a share for Decibel Therapeutics Inc. DBTX, +1.09%, a 43% premium over its closing price of $2.79 a share in the previous session. Boston-based Decibel Therapeutics is a clinical-stage biotechnology company with a focus on discovering and developing transformative treatments to restore and improve hearing and balance.
Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemotherapy Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemotherapy
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, being held in Los Angeles, California May 16 – 20th, 2023.
Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting
BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present findings from its drug discovery and development programs at the 46th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held in Orlando, Florida February 11–15, 2023.
Decibel Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will be participating in the following upcoming investor conferences in September.
Decibel Therapeutics Delivers Solid Interim Data From Cisplatin-Associated Hearing Loss Study
Decibel Therapeutics Inc (NASDAQ: DBTX) reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020 to protect against hearing loss in cancer patients receiving cisplatin chemotherapy. The interim analysis showed that 88% of.
Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference
BOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that John Lee, chief development officer, and Lis Leiderman, M.D., MBA, chief financial officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 9:00 a.m. ET.
Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference
BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference. The fireside chat will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. E.T.
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, being held virtually and in Washington D.C. May 15-19, 2022.
Decibel Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 3:00 p.m. ET.
Decibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) Meeting
BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug discovery and development programs at the 45th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held virtually February 5–9, 2022.
Decibel Therapeutics to Present at the H.C. Wainwright BioConnect Conference
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright BioConnect Conference. The fireside chat will be available for on-demand viewing starting Monday, January 10, 2022 at 7:00 am ET.
Decibel Therapeutics to Present at the Barclays Gene Editing & Gene Therapy Summit
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced its participation in the fifth annual Barclays Gene Editing & Gene Therapy Summit on Monday, November 15, 2021. Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at 3:30 pm ET and in a panel discussion titled “Addressing Development Challenges and the Regulatory Hurdles” at 4:45 pm ET.
Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit
BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 10:30 am ET.
Decibel Therapeutics Announces Publication of Foundational Study of Noise-related Inner Ear Damage
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that findings from a study of noise-related inner ear damage conducted in collaboration with the University of Maryland School of Medicine (UMSOM) and the Karolinska Institute (KI) have been published in Cell Reports .
Decibel Therapeutics' Hearing Loss Gene Therapy Receives FDA Orphan Drug Tag
The FDA has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to Decibel Therapeutics Inc (NASDAQ: DBTX) lead gene therapy product candidate, DB-OTO, for otoferlin-related congenital hearing loss. The Company looks forward to initiating a Phase 1/2 trial of DB-OTO in pediatric patients in 2022.
Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation and Rare Pediatric Disease Designation for the company's lead gene therapy product candidate, DB-OTO, for the treatment of patients with otoferlin-related congenital hearing loss.
Decibel Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the Company will participate in the following upcoming virtual investor conferences in September.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for DBTX.